VTRS Stock Overview
Operates as a healthcare company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Viatris Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.52 |
| 52 Week High | US$13.62 |
| 52 Week Low | US$9.93 |
| Beta | 0.95 |
| 1 Month Change | -6.36% |
| 3 Month Change | 9.35% |
| 1 Year Change | 17.56% |
| 3 Year Change | -8.41% |
| 5 Year Change | -35.56% |
| Change since IPO | 1,941.85% |
Recent News & Updates
Recent updates
Bargain Priced Viatris Reports Strong Q3 Earnings Results
Nov 08Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy
Oct 22Viatris: Revenues, Debt, Valuation And Strategy Under The Microscope
Jun 13Viatris: Skeptics Proven Right Once Again
May 30Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.
Apr 24Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential
Apr 08Viatris Stock Is Still Worth Buying
Mar 30Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued
Mar 02From Euphoria To Reality: Viatris' Tale Of Market Whirlwind
Jan 12Shareholder Returns
| VTRS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.08% | -0.3% | -2.7% |
| 1Y | 17.6% | 7.9% | 23.4% |
Return vs Industry: VTRS exceeded the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: VTRS underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| VTRS volatility | |
|---|---|
| VTRS Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: VTRS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VTRS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1961 | 32,000 | Scott Smith | www.viatris.com |
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
Viatris Inc. Fundamentals Summary
| VTRS fundamental statistics | |
|---|---|
| Market cap | US$14.94b |
| Earnings (TTM) | -US$883.30m |
| Revenue (TTM) | US$15.05b |
1.0x
P/S Ratio-16.9x
P/E RatioIs VTRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VTRS income statement (TTM) | |
|---|---|
| Revenue | US$15.05b |
| Cost of Revenue | US$8.72b |
| Gross Profit | US$6.32b |
| Other Expenses | US$7.21b |
| Earnings | -US$883.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 42.03% |
| Net Profit Margin | -5.87% |
| Debt/Equity Ratio | 79.5% |
How did VTRS perform over the long term?
See historical performance and comparisonDividends
3.8%
Current Dividend Yield-65%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 07:54 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Viatris Inc. is covered by 44 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Richard Silver | Barclays |